-
Sector Analysis
Heart Failure - Global Drug Forecast and Market Analysis to 2028
Heart failure( HF) is a clinical syndrome where the heart is unable to meet the demands of the body with a sufficient blood supply. This can be due to structural or functional cardiac abnormalities which can be caused by unexpected injury such as myocardial infarction, or an underlying pathogenesis such as hypertension (Krum and Abraham, 2009). The heart then begins to employ compensatory mechanisms that soon become maladaptive - Frank-Starling mechanism, neurohormonal activation and ventricular remodeling. All of which help...
-
Sector Analysis
PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026
Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual’s deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins...
-
Sector Analysis
PharmaPoint: Heart Failure – Global Drug Forecast and Market Analysis to 2026
GlobalData estimates sales of HF therapeutics to be approximately $3.7B across the 7MM in 2016, encompassing the US, the five major European markets (5EU: France, Germany, Italy, Spain and UK), and Japan. By 2026, GlobalData expects the HF market to grow at a strong Compound Annual Growth Rate (CAGR) of 15.7%, reaching sales of $16.1B by the end of the forecast period. Chronic HF therapeutics accounted for 95.9% of the total HF market in 2015, and despite the launch of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.